Sorry - yes, I did. Applied the Sweden rates.
I understand MSB is being pulled in all directions, but highlights the need to partner up so as to divide and conquer. Hospitals around USA and the world should be told about Rem-L and its benefits over steroids, and not wait for the FDA to direct patients to them.
That may be how MSB works, but if Novartis et al came on board, you can imagine there would be representatives in every hospital with kids with MIS-C and treating them.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-111
-
- There are more pages in this discussion • 313 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |